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In the low- and middle-income countries some non-communicable diseases (NCDs), such are
cardiac diseases, strokes, chronic lung diseases, certain cancers, and diabetes, tend to overtake the
morbidity and mortality of poverty diseases (Adams and Butterly, 2015; Jakovljevic and Getzen,
2016). Such diseases, conditionally labeled as diseases of aﬄuence (Nutrition Health Topics, 2016),
are growing rapidly in the developing countries, making almost 80% of deaths due to NCDs
(New WHO report: deaths from noncommunicable diseases on the rise, with developing world
hit hardest, 2011). Until a century ago, infectious diseases were the leading cause of morbidity and
mortality worldwide. For example, in the United States at the beginning of the twentieth century,
the crude death rate for the infectious diseases amounted to 800 per 100,000 population per year,
reaching nearly 1000 during influenza pandemic at the end of the WWII. Afterwards, significant
drop in the morbidity and mortality due to infectious causes was noticed, mostly as a consequence
of a variety of the conducted preventive measures in sanitation and hygiene area, vaccination
strategies and the development of different antimicrobial agents (Achievements in Public Health,
1900–1999: Control of Infectious Diseases, 1999; Wang et al., 2016). Due to the globalization, the
flow rate of people, ideas and financial capital increased worldwide (Jakovljevic et al., 2016).
Non-communicable diseases have achieved high morbidity and mortality rates, first in the
developed (aﬄuent) and afterwards in the low- and middle-income countries, dislodging the
rich-countries exclusivity premise. On the contrary, the wealthier people live, socially and
economically, the better their health (Fair Society Healthy Lives, 2010). Morbidity and mortality
rates are rising faster in developing countries; inequalities in health access within particular country
favor the growth of such rates (Human Development Report 2013, 2013). The chronic illnesses
make a profound impact on patients and society, regarding complex and expensive treatment
strategies, decreased quality of life and working disability. Most of them are treatable, but not
curable, which additionally prolongs the enormous influence on the health funds (Jakovljevic and
Milovanovic, 2015; EU Reflection on Chronic Disease, 2016). The objectives of this study were to
estimate the impact of drug utilization related to NCDs on Serbian health funds, and compare it
with the Gross National Income (GNI) per capita values for the observed period.
NON-COMMUNICABLE DISEASES IN SERBIA
Although, the life expectancy at birth for both sexes was increased by 3 years over the period of
2000–2012, in 2012 the loss of healthy life expectancy due to morbidity and disability was 9 years
lower than overall life expectancy at birth (Country Statistics Global Health Estimates by WHO
UN Partners, 2015; Jakovljevic et al., 2015a). Significant increase in treating cardiovascular diseases
(CVDs) contributed to such progress, although the adult risk factors as raised blood glucose,
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obesity, tobacco usage and raised blood pressure are slightly
higher in Serbia then the European average (Possible Directions
for Increasing Efficiency of Healthcare System in Serbia, 2015).
Mortality range for CVDs reached 762–744.9 per 100,000
population for a 10 years period (2004–2013), 259.4–294.4
for malignant neoplasms, 34.4–39.1 for diabetes and 34.2–
36.0 for chronic obstructive pulmonary disease (COPD; Health
statistical yearbook of Republic of Serbia, 2013). NCDs in
Serbia are estimated to account for 95% of all deaths, which
is significantly higher compared to the 86% of the European
region (EU Reflection on Chronic Disease, 2016). Mortality
due to cardiovascular diseases reached 54% of all deaths,
followed by cancers (23%), COPD (4%), and diabetes (3%)
(Noncommunicable Diseases (NCD) Country Profiles, 2015).
THE DATA REPORT
METHODS—DATABASES
Data obtained from the World Bank and OECD National
Accounts files concerning Serbia (Serbia, 2016) and from
the publications Marketing and consumption of medicinal
products for human use of Medicines and Medical Devices
Agency of Serbia (ALIMS) were observed for each year of
a ten-year period (2004–2013) (Marketing and consumption
of medicinal products for human use (2004–2013), 2016).
The quantum of Gross National Income per capita, obtained
by Atlas method and originally expressed in currency US$,
was observed and converted into euros using yearly average
exchange rates for each year. GNI per capita presents the
gross national income, converted to U.S. dollars using the
World Bank Atlas method, divided by the mid-year population.
GNI is the sum of value added by all resident producers
plus any product taxes that were not included in the
valuation of output plus net receipts of primary income from
abroad.
Medicine consumption for pharmacotherapy of the most
common NCDs and financial expenses were calculated
based on the World Health Organization (WHO) ATC
classification, for the following groups of drugs: A08-Antiobesity
preparations, excl. diet products, A10-Drugs used in diabetes,
B01-Antithrombotic agents, C-Cardiovascular system, L-
Antineoplastic and immunomodulating agents and R03-Drugs
for obstructive airway diseases. Expenses were expressed in euros
(EUR), consumption of medicines in Defined Daily Doses per
1000 inhabitants per day (DDD/1000 inh/day) and ratios as a
percentage of a total quantum (%).
DRUG UTILIZATION REGARDING THE GNI
Values of GNI per capita in Serbia recorded a rapid growth,
starting from 2004 to 2010, when a slight regression occurred
with a modest re-growing tendency in the period from 2011 to
2013. The expenses for indicated medicines followed the GNI
trend line, expressing an even more rapid growth of the financial
assets, especially in 2007 and 2008 (Figure 1; Jakovljevic et al.,
2015b).
In every particular year within the observed period, the
greatest funds were dedicated to the pharmacotherapy of
cardiovascular diseases. In the year 2008, it reached the highest
share of 25.5% regarding total medicine expenses. In the terms of
drug utilization in DDDs/1000 inh/day, the highest consumption
was in 2013 with the share of 44.38% of all prescribed medicines.
The funds for antineoplastic and immunomodulating agents
almost doubled their share within the observation period,
reaching the highest values in 2013, both in the financial and
utilization terms.
The expenses for drugs used in diabetes nearly tripled their
value in 2013 in comparison to 2004, whereby that was not
the case with the relative ratio regarding entire medicine funds,
which has remained more or less constant. The consumption
and its ratio followed the above-mentioned path of expenses
(Jakovljevic and Souliotis, 2016).
The drugs for obstructive airway diseases are at the fourth
place among pharmacotherapy resources, with the constant
growth in both terms, reaching the peak of the expenses and
consumption in 2011, in the nominal values as well as in ratio
terms.
The prescription of antithrombotic agents shows an
increasing tendency, together with increasing costs of treatment,
while decrease of consumption and consequently costs cutting
concerning antiobesity preparations, excl. diet products, was
noticed.
PHARMACOTHERAPY DATA COMPARED
TO THE COST OF ILLNESS
Approximately 10% of Serbian GDP was spent on the total health
care, thereof the share of government expenditure amounted
62%. Total pharmaceutical market in Serbia, with included
prescription and over-the-counter medicines, is estimated at
e645.6 million, with per capita expenditure estimated at e89.37.
National health insurance funds for medicines amounted e45.32
per capita in 2012, and reached 18% of total budget. Considering
the fact that NCDs are the most common cause of death, current
morbidity and mortality rates have to be reduced in order
to maintain sustainability of health care funds (Godman and
Gustafsson, 2014).
As a part of NCDs, cardiovascular diseases impose a
significant burden on the society, not only in terms of
morbidity and mortality, but also as a significant economic
impact. Amongst CVDs, stroke remains the main cause of
death, followed by cardiomyopathy and ischemic heart disease;
however, those diseases show no changes in the crude death rate
in 2012 compared to 2000. Hypertensive heart disease shows
growing tendency in the same time period (Noncommunicable
Diseases (NCD) Country Profiles, 2015). In order to estimate the
economic burden of cardiovascular diseases, a study conducted
in Serbia referring year 2009, evaluated their direct and indirect
costs from the point of view of the society. Total costs reached
514.3 million euros, the greatest part of which was influenced by
medications (29.94%; Lakic´ et al., 2014). According to the ALIMS
data, for the cardiovascular system disorders medicines only, it
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FIGURE 1 | Overall costs for pharmacotherapy of the most common NCDs compared with GNI for the selected time period. It can be observed that the
expenses for medicines followed the GNI trend line, expressing an even more rapid growth of the financial assets in years 2007 and 2008.
was necessary to refund between 80 and 180 million Euros per
each observed year (2004–2013; Table 1). If the expenses of the
antithrombotic agents are added to the cardiovascular medicines,
we can conclude that the cardiovascular diseases are a highly
costly group of diseases with a heavy burden on the society. It
is even more if we consider the fact that the total cost of illness
amounted to approximately 1.8% of the Serbian GDP (Lakic´
et al., 2014).
Ischemic heart disease is the leading cause of mortality and
morbidity, expressed in terms of disability-adjusted life years
(DALY). In Europe, ischemic heart disease accounted for 24.8%
of all the DALYs caused by other diseases, while in Serbia
it accounts for only 1% less (23.8%). In highly developed
countries, the mortality rate of ischemic heart disease has been
decreasing, due to better socio-economic conditions, increased
health protection service quality and healthy life styles promotion
(Jakovljevic et al., 2016). At the same time, mortality is high in
the east-European countries. In 2009, standard mortality rate
for Serbia amounted to 113.8 compared to the European Union
average of 87.2 per 100,000 inhabitants (Mickovski et al., 2011).
Serbian age standardized death rate regarding CVDs in 2014
of 400.8 per 100,000 males, was amongst highest in the whole
European region; e.g., in United Kingdom it amounted 140.6,
Denmark 134.6 and France 111.8 per 100,000 males (Global
status report on noncommunicable diseases 2014, 2014).
Calculated from the point of view of the society, the peculiarity
in the Serbian cost of illness calculations would be the fact that
only one fourth of all the expenses weremade up of indirect costs.
That differs from the developed countries data concerning the
treatment of CVDs in which indirect costs would reach almost
half of the total costs (Chan et al., 1996; Liu et al., 2002).
Worldwide, cancer represents an important public health and
economic issue, as the global cancer incidence in 2012 was 14.1
million with 8.2 million death cases (Worldwide cancer statistics,
2014). In 2014 the age standardized death rate from cancers
in Serbia reached 218.1, while in UK, Denmark and France it
amounted 153.9, 179.9, and 179.8 per 100,000 males, respectively
(Global status report on noncommunicable diseases 2014, 2014).
Cancer treatment costs impose considerable expenses on the
national health system budgets, reaching in average 9.1% of the
Gross Domestic Product Expenditure on Health (GDPHE) for
developed European countries, up to 17.1% in USA in 2010
(Pritchard et al., 2016). On average, 10% of total health care
costs in developed countries are also spent on treating cancer
(Bosanquet and Sikora, 2004).
Differences in costs occur not only due to different types of
cancer, but also as a consequence of the stage of the disease
(Dagovic et al., 2014). Based on the research conducted in
the central Serbian region the same authors concluded, that
in the total costs of cancer care the medication share reached
5%, while malignant breast neoplasm turned out to be the
most expensive overall treatment. For the patients with the
advanced stage of cancer, the greatest impact on total medical
treatment costs was observed concerningmedicines expenditures
(Kovacevic et al., 2015a). Significant costs are obtained for
colorectal cancer pharmacotherapy, depending upon the stage of
cancer. In Serbian settings, it was necessary to pay from 4200 to
20,600 Euros per patient with metastatic disease (Kovacevic et al.,
2015b). The data obtained from the ALIMS show a significant
fivefold increase in the expenses and more than twofold increase
of consumption of antineoplastic and immunomodulating agents
in 2013 compared to 2004 (Jakovljevic et al., 2014a).
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TABLE 1 | Expenses (EUR) and consumption of the specific medicine
groups for the selected years and ratios regarding their total spending
and consumption (%).
Year Expenses
(EUR)
% of total
spending on
medicines
Consumption
(*DDD/1000
inh/day)
% of total
consumption
C—CARDIOVASCULAR SYSTEM
2004 78.716.560,68 23,20 331,02 30,54
2005 83.534.063,75 21,94 334,63 30,57
2006 122.294.456,31 23,94 387,81 38,26
2007 158.399.085,91 23,04 400,06 36,89
2008 203.799.903,76 25,50 481,70 39,51
2009 161.297.625,34 21,74 414,67 35,21
2010 162.352.661,21 22,89 384,73 39,82
2011 163.667.924,49 22,66 474,31 42,94
2012 176.571.683,75 23,80 526,98 42,44
2013 182.656.566,45 22,99 568,28 44,38
L—ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
2004 19.166.161,32 5,65 1,52 0,14
2005 23.112.621,92 6,07 1,49 0,14
2006 30.880.478,61 6,05 2,12 0,21
2007 49.424.984,02 7,19 2,32 0,21
2008 60.977.545,27 7,63 2,32 0,19
2009 68.839.374,51 9,28 2,71 0,23
2010 77.515.115,27 10,93 2,38 0,25
2011 68.873.960,86 9,54 2,19 0,20
2012 75.968.428,70 10,24 3,32 0,27
2013 89.944.696,11 11,32 3,61 0,28
A10—DRUGS USED IN DIABETES
2004 13.673.374,33 4,03 15,88 1,46
2005 21.607.559,81 5,68 27,51 2,51
2006 23.647.892,69 4,63 41,82 4,13
2007 28.566.352,17 4,15 41,18 3,80
2008 35.355.225,48 4,42 59,68 4,90
2009 30.357.067,89 4,09 49,31 4,19
2010 34.022.142,79 4,80 45,73 4,73
2011 36.770.569,28 5,09 45,19 4,09
2012 37.668.755,11 5,08 74,50 6,00
2013 42.739.770,26 5,38 79,97 6,25
R03—DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
2004 8.758.308,28 2,58 18,40 1,70
2005 9.751.546,83 2,56 17,47 1,60
2006 16.558.281,51 3,24 26,87 2,65
2007 16.745.056,96 2,44 23,09 2,13
2008 19.043.385,18 2,38 25,53 2,09
2009 24.353.872,40 3,28 18,40 1,56
2010 26.190.593,19 3,69 23,17 2,40
2011 26.784.686,01 3,71 23,22 2,10
2012 22.604.678,59 3,05 15,06 1,21
2013 25.425.617,85 3,20 18,55 1,45
B01—ANTITHROMBOTIC AGENTS
2004 2.994.811,70 0,88 11,00 1,01
2005 7.020.869,89 1,84 19,80 1,81
2006 11.245.999,68 2,20 29,08 2,87
2007 18.433.025,18 2,68 55,44 5,11
2008 24.131.961,20 3,02 54,32 4,46
(Continued)
TABLE 1 | Continued
Expenses
(EUR)
% of total
spending on
medicines
Consumption
(*DDD/1000
inh/day)
% of total
consumption
2009 24.750.838,47 3,34 69,16 5,87
2010 29.334.215,64 4,14 58,82 6,09
2011 23.823.928,51 3,30 67,94 6,15
2012 30.130.846,05 4,06 73,34 5,91
2013 29.289.470,21 3,69 89,68 7,00
A08—ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
2004 711.589,90 0,21 0,10 0,01
2005 1.033.497,60 0,27 0,17 0,02
2006 1.313.206,95 0,26 0,22 0,02
2007 1.320.202,45 0,19 0,23 0,02
2008 1.413.316,40 0,18 0,25 0,02
2009 1.295.245,35 0,17 0,30 0,03
2010 524.148,20 0,07 0,10 0,01
2011 474.353,52 0,07 0,09 0,01
2012 402.346,66 0,05 0,08 0,01
2013 402.979,73 0,05 0,08 0,01
Total
medicines
expenses(EUR)
Total
*DDD/inh/day
2004 339.279.303,77 1.083,97
2005 380.716.701,39 1.094,61
2006 510.833.609,54 1.013,70
2007 687.588.174,80 1.084,34
2008 799.082.221,00 1.219,07
2009 741.981.960,19 1.177,72
2010 709.317.344,16 966,26
2011 722.207.154,57 1.104,57
2012 742.013.975,72 1.241,66
2013 794.560.044,61 1.280,47
*DDD/1000 inh/day, Defined Daily Doses per 1000 inhabitants per day.
The cost of diabetes mellitus, with its high morbidity and
mortality rates, imposes significant burden on the national
healthcare system of Serbia. The Institute of Public Health of
Serbia mortality estimates were 39.1 per 100,000 population, but
morbidity data show the presence of almost half a million people
with this illness (Health statistical yearbook of Republic of Serbia,
2013). Compared to some European countries, e.g., Greece, the
death rate equals only 6.6 per 100,000 males (Global status report
on noncommunicable diseases 2014, 2014). The theoretical cost
of handling this disease would even reach 6% of the total Serbian
health care expenditure or 11% of the annual Health insurance
fund budget (Jakovljevic, 2014). In real life, these costs would
be considerably lower, since not all the population is covered by
health insurance. Data concerning developed countries, such as
Switzerland, show that 2.2% of the total health care expenditure
is spent on the specific diabetes care (Schmitt-Koopmann et al.,
2004), while in the United States 10–20% of the health budgets
are spent on diabetes mellitus treatment (American Diabetes
Association, 2008). Based on the research conducted by Biorac
et al. (2009), medicine share in overall costs of illness for the year
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2007 reached 38% in Serbia. An increasing trend in insulin and its
analogs as well as oral antidiabetics consumption was observed.
The ALIMS showed a fourfold increase in drug consumption for
diabetes treatment and a threefold increase in expenses in 2013 in
comparison to 2004. Antidiabetic medication share in the overall
consumption showed a rapid growth in the observed period, but
that was not the case with the costs, whose share in total expenses
was only 5.38% in 2013 compared with 4.03% in 2004 (Table 1).
As a severe disabling and irreversible illness, COPD is
standing among top five most expensive chronic disorders due
to its high healthcare budget impact. Its estimated prevalence in
developed countries makes 4–6% among adult males as well as
1–3% among females, with smoking as a dominant risk factor.
The COPD patients often have different severe comorbidities that
rise costs of treatment andmake distinction from the basic illness
difficult. The greatest contributing factors in overall treatment
costs are periodic exacerbations of the disease, which are
getting higher with the COPD severity degree (Andersson et al.,
2002). The major cost drivers in the developed countries would
be physician consultations and surgery, while in the middle-
income eastern countries, pharmaceuticals and oxygen costs are
dominant. In Serbia, the incidence of COPD mortality is almost
equal to the one of the diabetes (Health statistical yearbook
of Republic of Serbia, 2013). COPD related pharmaceutical
prescription reached the peak of the value turnover in 2011,
with almost 27 million Euros, while the consumption of such
medicines remained constant, with lesser pop outs, in the
entire observational period (Table 1). The similar situation was
observed in the entire western Balkan market, when value of
medicines for the treatment of the respiratory diseases rose to
46.5 million Euros in 2012. COPD comorbidities significantly
contributed to the greater costs of medical care, e.g. costs
of community acquired pneumonia (CAP) clinical treatment
accounted for an average 717 Euros in a 1 month, while COPD
and CAP together accounted for 970 Euros during the same
time period (Cupurdija, 2015). According to the results from a
recent published study, concerning comparison of two different
markets, Serbian and Belgian, drug acquisition costs (in- and
outpatient consumption) of COPD treatment reached up to 54%
in Serbian and 46% in Belgian sample. The greatest difference
actually occurred in the relative number of hospital bed days
and hospital admissions due to exacerbation of the disease, per
person, which were significantly smaller in Belgian population
(Jakovljevic et al., 2013).
Obesity is present in the Serbian population in 24.8% of the
adult population. This ratio is increasing; some forecasts predict
that in 2020, 44% of men and 31% of women will be obese
(Nutrition, Physical Activity and Obesity, 2013). Consumption
and expenses of medicines concerning this disease are not
following the predicted path, since their significant decrease
occurred in 2008, making only 0.01% of total drugs consumption
as well as 0.05% of the overall expenses (Table 1). We strongly
support other anti-obesity measures, such as promoting healthy
life style, which wouldmake a significantly higher contribution in
the management of this problem, rather than pharmacotherapy
(Jakovljevic and Ogura, 2016).
CONCLUSION
Almost 80% of all deaths due to chronic diseases like CVDs,
cancer, COPD and diabetes occur in the low- and middle-income
countries. The rapid aging of the Serbian population (Jakovljevic
and Laaser, 2015), with higher demands for the healthcare
services, along with the difficulties in transitional national health
insurance fund functioning, have resulted in the huge impact on
the national budget as well as household expenditures (Ogura and
Jakovljevic, 2014).
This data report shows that the total pharmacotherapy costs
of treating CVDs in Serbia followed the GNI trend line, with
noticeably constant growth of the financial assets. Expenses
of medicines reached highest values in 2008 and 2013, even
overgrowing the GNI rising trends.
Together with measures of prevention, chronic disease
morbidity and mortality can be significantly reduced if
pharmacotherapy is accessible and affordable. There have to be
more initiatives and real-life activities in order to alleviate one’s
access to the treatment, as well as to improve governmental
interventions aiming to facilitate the affordability of the drugs
used to treat chronic diseases (Jakovljevic et al., 2015c).
One of the efficient measures could involve expanding the
National Health Insurance Fund Drug List, both with brands
and generic equivalents (Jakovljevic et al., 2014b). In addition,
a certain part of health funds must be dedicated to substantial
promotion of healthy life styles and minimizing verified risk
factors for the occurrence of NCDs.
Possible limitations of the study would likely be the
underestimated drugs utilization and pharmacotherapy costs for
the particular diseases. In treating most NCDs, many different
medications are used, not only those within specified ATC
groups, but for other concomitant diseases, which could elevate
calculated costs. Calculations did not comprehend the out-of-
pocket expenses for different Over the Counter medicines due
to no published data regarding their consumption. Drug prices
data within the ALIMS publications database are calculated using
regulatory approved drug prices, not the real values ensued from
the special terms of sale.
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